Newsfeed

This area is a possible form of presentation for the integration of news sources relating to listed companies.
The presentation level is a template based on short news services, where users can get a quick overview of the latest news. The detailed views enable further research if interested.

This newsfeed is a compilation of current news from direct connections of TopTier NewsWire services related to listed companies. This feed is for demonstration purposes only. Sector-specific news, public relations and product information can be accessed via the GICS portals > Sector Intelligence section.

US62855J1043
Reset filter
Do you already know our new terminal view? Click here.
FIGI: BBG000D9H9F1
MYGN

Myriad Genetics Inc
GICS: Health Care · SECTOR: EQTY · SUB-SECTOR: Diagnostics & Research · THEMEFOLIO: $HLTH
NAME
Myriad Genetics Inc
ISIN
US62855J1043
TICKER
MYGN
MIC
XNAS
REUTERS
MYGN.OQ
BLOOMBERG
MYGN US
Thu, 19.12.2024       Myriad Genetics

Myriad Genetics announced a MyRisk® Hereditary Cancer Test with RiskScore® study was named as one of the top 10 significant advances in genomic medicine....
Tue, 10.12.2024       Myriad Genetics

Myriad Genetics provides update on discussions with UnitedHealthcare regarding medical policy for pharmacogenetic testing....
Tue, 10.12.2024       Myriad Genetics

Myriad Genetics announced the election of Mark S. Davis to its Board of Director, effective immediately, expanding the Board from eight to nine members....
Mon, 09.12.2024       Myriad Genetics

Myriad Genetics, Inc. announced it will present new data at the 2024 San Antonio Breast Cancer Symposium....
Thu, 14.11.2024       Myriad Genetics

Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Myriad Genetics, Inc. (“Myriad” or “the Company”) (NASDAQ: MYGN). Investors who purchased Myriad securities are encouraged to obtain additional information and assist the investigation by visiting the firm’s site: bgandg.com/MY...
Wed, 13.11.2024       Myriad Genetics

NEW YORK, Nov. 13, 2024 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Myriad Genetics, Inc. ("Myriad" or "the Company") (NASDAQ: MYGN). Investors who purchased Myriad securities are encouraged to obtain additional information and assist the investigation...
Wed, 13.11.2024       Myriad Genetics

Myriad Genetics announced SneakPeek is now available over the counter in more than 8,800 retail locations....
Thu, 07.11.2024       Myriad Genetics

Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Myriad Genetics, Inc. (“Myriad” or “the Company”) (NASDAQ: MYGN). Investors who purchased Myriad securities are encouraged to obtain additional information and assist the investigation by visiting the firm’s site: bgandg.com/MY...
Wed, 06.11.2024       Myriad Genetics

NEW YORK, Nov. 6, 2024 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Myriad Genetics, Inc. ("Myriad" or "the Company") (NASDAQ: MYGN). Investors who purchased Myriad securities are encouraged to obtain additional information and assist the investigation...
Wed, 30.10.2024       Myriad Genetics

Myriad Genetics, Inc. (NASDAQ: MYGN) will hold its third quarter earnings conference call on Thursday, Nov. 7, 2024 at 4:30 pm ET....
Silent Ad
Tue, 15.10.2024       Myriad Genetics

Myriad Genetics and Flatiron Health partner to make genetic testing more accessible with EMR integration...
Tue, 08.10.2024       Myriad Genetics

SALT LAKE CITY, Oct. 08, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced a series of ongoing research collaborations to study the use of molecular residual disease (MRD) testing in breast cancer using Myriad’s Precise® MRD test....
Thu, 03.10.2024       Myriad Genetics

SALT LAKE CITY and FREMONT, Calif., Oct. 03, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, and Ultima Genomics, Inc., a developer of a revolutionary new ultra-high throughput next-generation sequencing (NGS) platform, today announced a joint effort to explore Ultima’s UG 100™ s...
Tue, 01.10.2024       Myriad Genetics

SALT LAKE CITY, Oct. 01, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced that the United States Patent and Trademark Office has issued a third patent that will strengthen its ability to deliver a tumor-informed, high-definition, molecular residual disease (MRD) as...
Wed, 21.08.2024       Myriad Genetics

SALT LAKE CITY, Aug. 21, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced Myriad management will participate in two upcoming investor healthcare conferences....
Wed, 17.07.2024       Myriad Genetics

New Nationwide Survey Findings Show That More Than Half of Women Do Not Know That Breast Density Can Reveal Increased Risk of Breast Cancer New Nationwide Survey Findings Show That More Than Half of Women Do Not Know That Breast Density Can Reveal Increased Risk of Breast Cancer...
Thu, 11.07.2024       Myriad Genetics

SALT LAKE CITY and FREMONT, Calif., July 11, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq: MYGN), a leader in genetic testing and precision medicine, and Personalis, Inc. (Nasdaq: PSNL) today announced that they have entered into an agreement to cross-license patent estates covering tumor-informed approaches to detect minimal residual d...
Tue, 09.07.2024       Myriad Genetics

SALT LAKE CITY, July 09, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced that the United States Patent and Trademark Office has issued a second patent that will strengthen its ability to deliver a tumor-informed, high-definition, molecular residual disease (MRD) a...
Tue, 02.07.2024       Myriad Genetics

SALT LAKE CITY, July 02, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced it has received the Great Place To Work Certification for the second year in a row. The certification is based entirely on what current employees say about their experience working at Myriad....
Mon, 24.06.2024       Myriad Genetics

New Findings from Myriad Genetics Reveal One-Third of Americans Say Election Season Affects Their Mental Health New Findings from Myriad Genetics Reveal One-Third of Americans Say Election Season Affects Their Mental Health...
Silent Ad
Thu, 30.05.2024       Myriad Genetics

VENLO, The Netherlands and SALT LAKE CITY, May 30, 2024 (GLOBE NEWSWIRE) -- QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) and Myriad Genetics (NASDAQ: MYGN) today announced they will develop a globally distributable kit-based test for analyzing Homologous Recombination Deficiency (HRD) status. This next-generation sequencing (NGS) test aims...
Thu, 23.05.2024       Myriad Genetics

Molecular Residual Disease (MRD) study and multiple RiskScore studies among seven new datasets to be shared by Myriad and Collaborators Molecular Residual Disease (MRD) study and multiple RiskScore studies among seven new datasets to be shared by Myriad and Collaborators...
Thu, 16.05.2024       Myriad Genetics

Myriad’s Prolaris Test is the only biomarker test to quantify the benefits of adding androgen deprivation therapy to radiation therapy1...
Tue, 07.05.2024       Myriad Genetics

SALT LAKE CITY, May 07, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced the reorganization of its European operations to better align company resources to its domestic opportunities while continuing to serve key biopharma partners and patients outside the United S...